Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Eur J Radiol. 2021 Jan 12;136:109539. doi: 10.1016/j.ejrad.2021.109539

Figure 2. Kaplan-Meier curve of overall survival by hepatotoxicity.

Figure 2.

Patients with ≥grade 3 hepatotoxicity attributed to transarterial radioembolization (TARE) had a significantly lower median survival of 6 months compared with patients without toxicity who survived a median of 16 months (p<0.001).